On Monday, Shares of Exelixis, Inc. (NASDAQ:EXEL), skyrocketed 50.38% to $5.88, hitting its highest level.
Exelixis, declared positive top-line results from the primary analysis of METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have practiced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor (TKI).
The trial met its primary endpoint of demonstrating a statistically noteworthyenhance in progression-free survival (PFS) in the first 375 randomized patients as determined by an independent radiology committee (IRC). Cabozantinib reduced the risk of disease progression or death by 42 percent contrast to the everolimus arm (hazard ratio [HR]=0.58, 95 percent CI 0.45-0.75, p<0.0001).
Data pertaining to overall survival (OS) in the entire study population of 658 patients, a secondary endpoint of the trial, were immature at the data cutoff. A pre-specified interim analysis, triggered by the primary analysis for PFS, showed a trend in OS favoring cabozantinib (HR = 0.67, unadjusted 95 percent CI 0.51 - 0.89; p=0.005). At the time of the interim analysis, the pre-specified p-value of 0.0019 to achieve statistical significance was not reached. The trial will continue to the final analysis of OS anticipated in 2016.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Shares of Horizon Pharma plc (NASDAQ:HZNP), inclined 3.32% to $38.31, during its last trading session, hitting its highest level.
Horizon Pharma plc, declared predictable record net sales results for the second quarter ended June 30, 2015.
The company estimates net sales in the range of $170 to $172 million for the second quarter of 2015, which represents an enhance of about 160 percent as contrast to the second quarter of 2014 and an enhance of about 50 percent as contrast to the first quarter of 2015. While second quarter adjusted EBITDA and additional results will be offered as part of the second quarter 2015 earnings release, adjusted EBITDA margin for the second quarter of 2015 is predictable to be significantly improved as compared to the first quarter of 2015. Cash and cash equivalents as of June 30, 2015, is predictable to be about $668 million, an enhance of $124 million from the March 31, 2015, cash and cash equivalents balance of $544 million.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Finally, MasterCard Incorporated (NYSE:MA), ended its last trade with 1.23% gain, and closed at $97.26, hitting its highest level.
MasterCard Incorporated, is giving fans using Apple Pay an easy, secure and private way to pay at the 2015 MLB All-Star Game presented by T-Mobile in Cincinnati, together with a Priceless experience. Those attending the 2015 MLB All-Star Week festivities will not only be able to use Apple Pay on-site for food and merchandise purchases, but when they do they could also receive a Priceless Surprise.
MasterCard cardholders who use Apple Pay at contactless merchandise and concession acceptance locations at the T-Mobile All-Star FanFest taking place July 10th through July 14th or in-stadium at Great American Ball Park from July 12th through July 14th could get a little something extra – from All-Star branded premiums, autographed memorabilia to prepaid cards and more.
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.